Director of Oncology Marketing, Hereditary Cancer Testing at Natera

San Carlos, California, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Diagnostics, Pharmaceuticals, OncologyIndustries

Requirements

Bachelor’s degree in life sciences required; MBA or PhD strongly preferred
Minimum of 10 years of experience in diagnostics, biotech, or pharmaceutical marketing, with a focus on oncology or genomics
Direct experience with hereditary cancer testing is highly desirable
Willingness to travel up to 25% for advisory boards, conferences, sales/marketing meetings, and customer engagements

Responsibilities

Develop and execute strategic and tactical marketing plans for Empower
Collaborate cross-functionally to align messaging with market needs and clinical evidence
Identify key market opportunities and gaps; drive initiatives to meet or exceed commercial goals
Lead the development of marketing assets and sales enablement tools tailored to the Empower product
Manage agency and vendor relationships to build and execute integrated campaigns
Support Empower’s alignment and positioning within the broader oncology testing ecosystem
Present marketing strategies, insights, and campaign performance to executive leadership
Perform other duties as assigned

Skills

Oncology Marketing

Hereditary Cancer Testing

Genetic Testing

Marketing Strategy

Cross-functional Leadership

Sales Enablement

Market Analysis

Campaign Management

Vendor Management

Clinical Messaging

Patient Messaging

Genomics

Natera

Genetic testing and diagnostics solutions provider

About Natera

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services. The company's goal is to improve patient care and health outcomes through accurate genetic testing.

Austin, TexasHeadquarters

2004Year Founded

$149.9MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

1,001-5,000Employees

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Risks

Hindenburg report accuses Natera of deceptive sales practices, risking legal challenges.

New Prospera Heart features may face slow adoption by healthcare providers.

Fetal RhD NIPT demand may drop post-RhIg shortage, affecting future sales.

Differentiation

Natera's Signatera test offers personalized ctDNA analysis for cancer patients.

Prospera Heart test uses unique Donor Quantity Score for transplant rejection detection.

Panorama NIPT test is a leader in non-invasive prenatal testing with 2 million tests.

Upsides

Increased adoption of liquid biopsy techniques boosts demand for Natera's cfDNA tests.

AI integration enhances accuracy and speed of Natera's cfDNA analysis.

Growing personalized medicine trend aligns with Natera's customized genetic tests.

Land your dream remote job 3x faster with AI

Try Jobo Free